Your browser doesn't support javascript.
loading
Efficacy and safety results of ABT-414 in combination with radiation and temozolomide in newly diagnosed glioblastoma.
Reardon, David A; Lassman, Andrew B; van den Bent, Martin; Kumthekar, Priya; Merrell, Ryan; Scott, Andrew M; Fichtel, Lisa; Sulman, Erik P; Gomez, Erica; Fischer, JuDee; Lee, Ho-Jin; Munasinghe, Wijith; Xiong, Hao; Mandich, Helen; Roberts-Rapp, Lisa; Ansell, Peter; Holen, Kyle D; Gan, Hui K.
Afiliación
  • Reardon DA; Center for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts; Department of Neurology & Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, New York; Neuro-Oncology Unit, Erasmus MC Cancer Center, Rotterdam, the Netherlands; Department of N
  • Lassman AB; Center for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts; Department of Neurology & Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, New York; Neuro-Oncology Unit, Erasmus MC Cancer Center, Rotterdam, the Netherlands; Department of N
  • van den Bent M; Center for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts; Department of Neurology & Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, New York; Neuro-Oncology Unit, Erasmus MC Cancer Center, Rotterdam, the Netherlands; Department of N
  • Kumthekar P; Center for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts; Department of Neurology & Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, New York; Neuro-Oncology Unit, Erasmus MC Cancer Center, Rotterdam, the Netherlands; Department of N
  • Merrell R; Center for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts; Department of Neurology & Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, New York; Neuro-Oncology Unit, Erasmus MC Cancer Center, Rotterdam, the Netherlands; Department of N
  • Scott AM; Center for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts; Department of Neurology & Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, New York; Neuro-Oncology Unit, Erasmus MC Cancer Center, Rotterdam, the Netherlands; Department of N
  • Fichtel L; Center for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts; Department of Neurology & Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, New York; Neuro-Oncology Unit, Erasmus MC Cancer Center, Rotterdam, the Netherlands; Department of N
  • Sulman EP; Center for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts; Department of Neurology & Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, New York; Neuro-Oncology Unit, Erasmus MC Cancer Center, Rotterdam, the Netherlands; Department of N
  • Gomez E; Center for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts; Department of Neurology & Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, New York; Neuro-Oncology Unit, Erasmus MC Cancer Center, Rotterdam, the Netherlands; Department of N
  • Fischer J; Center for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts; Department of Neurology & Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, New York; Neuro-Oncology Unit, Erasmus MC Cancer Center, Rotterdam, the Netherlands; Department of N
  • Lee HJ; Center for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts; Department of Neurology & Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, New York; Neuro-Oncology Unit, Erasmus MC Cancer Center, Rotterdam, the Netherlands; Department of N
  • Munasinghe W; Center for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts; Department of Neurology & Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, New York; Neuro-Oncology Unit, Erasmus MC Cancer Center, Rotterdam, the Netherlands; Department of N
  • Xiong H; Center for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts; Department of Neurology & Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, New York; Neuro-Oncology Unit, Erasmus MC Cancer Center, Rotterdam, the Netherlands; Department of N
  • Mandich H; Center for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts; Department of Neurology & Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, New York; Neuro-Oncology Unit, Erasmus MC Cancer Center, Rotterdam, the Netherlands; Department of N
  • Roberts-Rapp L; Center for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts; Department of Neurology & Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, New York; Neuro-Oncology Unit, Erasmus MC Cancer Center, Rotterdam, the Netherlands; Department of N
  • Ansell P; Center for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts; Department of Neurology & Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, New York; Neuro-Oncology Unit, Erasmus MC Cancer Center, Rotterdam, the Netherlands; Department of N
  • Holen KD; Center for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts; Department of Neurology & Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, New York; Neuro-Oncology Unit, Erasmus MC Cancer Center, Rotterdam, the Netherlands; Department of N
  • Gan HK; Center for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts; Department of Neurology & Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, New York; Neuro-Oncology Unit, Erasmus MC Cancer Center, Rotterdam, the Netherlands; Department of N
Neuro Oncol ; 19(7): 965-975, 2017 Jul 01.
Article en En | MEDLINE | ID: mdl-28039367
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Encefálicas / Glioblastoma / Inmunoconjugados / Dacarbazina / Anticuerpos Monoclonales Humanizados / Antineoplásicos Tipo de estudio: Clinical_trials / Diagnostic_studies / Prognostic_studies Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Neuro Oncol Asunto de la revista: NEOPLASIAS / NEUROLOGIA Año: 2017 Tipo del documento: Article Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Encefálicas / Glioblastoma / Inmunoconjugados / Dacarbazina / Anticuerpos Monoclonales Humanizados / Antineoplásicos Tipo de estudio: Clinical_trials / Diagnostic_studies / Prognostic_studies Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Neuro Oncol Asunto de la revista: NEOPLASIAS / NEUROLOGIA Año: 2017 Tipo del documento: Article Pais de publicación: Reino Unido